Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
570.11B
Market cap570.11B
Price-Earnings ratio
20.91
Price-Earnings ratio20.91
Dividend yield
2.23%
Dividend yield2.23%
Average volume
10.18M
Average volume10.18M
High today
$235.20
High today$235.20
Low today
$230.06
Low today$230.06
Open price
$231.36
Open price$231.36
Volume
9.32M
Volume9.32M
52 Week high
$235.20
52 Week high$235.20
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $233.38. The company's market cap stands at 570.11B, with a P/E ratio of 20.91 and a dividend yield of 2.2%.

On 2026-02-03, Johnson & Johnson(JNJ) stock traded between a low of $230.06 and a high of $235.20. Shares are currently priced at $233.38, which is +1.4% above the low and -0.8% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 9.32M, against a daily average of 10.18M.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $235.20 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $235.20 at its peak.

JNJ News

TipRanks 8h
Johnson & Johnson price target raised to $255 from $240 at RBC Capital

RBC Capital raised the firm’s price target on Johnson & Johnson to $255 from $240 and keeps an Outperform rating on the shares. The company is unlikely to undo...

Simply Wall St 1d
Stronger Earnings and Oncology Wins Might Change The Case For Investing In Johnson & Johnson

Johnson & Johnson recently reported fourth-quarter 2025 sales of US$24,564 million and full-year 2025 sales of US$94,193 million, alongside FDA approval of DARZ...

Stronger Earnings and Oncology Wins Might Change The Case For Investing In Johnson & Johnson
Simply Wall St 2d
Assessing Johnson & Johnson Valuation After Strong Results Guidance And New DARZALEX FASPRO Approval

Johnson & Johnson (JNJ) is back in focus after a run of upbeat news, including strong fourth quarter and full year 2025 results, fresh 2026 sales guidance, and...

Assessing Johnson & Johnson Valuation After Strong Results Guidance And New DARZALEX FASPRO Approval

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
35.7%
Sell
7.1%

More JNJ News

TipRanks 3d
Alphabet, Intel, Micron, J&J, Adobe Insider Moves

Insiders have been trading these 5 stocks: ((GOOG)), ((INTC)), ((MU)), ((JNJ)) and ((ADBE)). Here is a breakdown of their recent trades and their value. Claim 5...

Simply Wall St 3d
Johnson & Johnson Weighs Oncology Progress Against Easing Talc Legal Risks

FDA approved expanded use of DARZALEX FASPRO combination therapy for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. A long runn...

Johnson & Johnson Weighs Oncology Progress Against Easing Talc Legal Risks
The Motley Fool 4d
This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy?

Johnson & Johnson is a picture of stability. Johnson & Johnson (JNJ 0.02%), a leading healthcare giant, has been around for over 100 years and has achieved a l...

This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy?
Simply Wall St 4d
Have Johnson & Johnson Insiders Been Selling Stock?

Some Johnson & Johnson ( ) shareholders may be a little concerned to see that the CEO & Chairman, Joaquin Duato, recently sold a substantial US$22m worth of sto...

Have Johnson & Johnson Insiders Been Selling Stock?
Nasdaq 5d
March 13th Options Now Available For Johnson & Johnson

Investors in Johnson & Johnson (Symbol: JNJ) saw new options become available today, for the March 13th expiration. At Stock Options Channel , our YieldBoost fo...

March 13th Options Now Available For Johnson & Johnson
TipRanks 5d
Johnson & Johnson CEO Dumps $22M in Stock Post Q4 Results. Should Investors Worry?

Johnson & Johnson (JNJ) CEO Joaquin Duato has sold a major block of company stock just days after the healthcare giant reported mixed fourth-quarter results. Ac...

Simply Wall St 5d
Johnson & Johnson Highlights Cancer Drug Expansion And Robotic Surgery Push

Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in a new combination therapy for newly diagnosed multiple myeloma patients who are inelig...

Johnson & Johnson Highlights Cancer Drug Expansion And Robotic Surgery Push

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.